HB Wealth Management LLC Sells 3,326 Shares of Becton, Dickinson and Company $BDX

HB Wealth Management LLC lowered its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 10.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 29,324 shares of the medical instruments supplier’s stock after selling 3,326 shares during the period. HB Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $5,691,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Activest Wealth Management raised its holdings in shares of Becton, Dickinson and Company by 285.3% during the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 97 shares in the last quarter. Imprint Wealth LLC acquired a new position in shares of Becton, Dickinson and Company during the 3rd quarter worth $25,000. SOA Wealth Advisors LLC. raised its holdings in shares of Becton, Dickinson and Company by 256.8% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 95 shares in the last quarter. Steph & Co. raised its holdings in shares of Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 65 shares in the last quarter. Finally, Accredited Wealth Management LLC raised its holdings in shares of Becton, Dickinson and Company by 77.8% during the 3rd quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 70 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the sale, the director owned 36,763 shares in the company, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In the last 90 days, insiders sold 1,103 shares of company stock valued at $202,870. Insiders own 0.40% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on BDX shares. Jefferies Financial Group lowered their price target on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Argus lowered their price target on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a report on Monday, March 23rd. Wells Fargo & Company reduced their price objective on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 10th. JPMorgan Chase & Co. reduced their price objective on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 10th. Finally, Barclays started coverage on Becton, Dickinson and Company in a research report on Tuesday, February 10th. They set an “overweight” rating and a $202.00 price objective on the stock. Six equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to data from MarketBeat, Becton, Dickinson and Company currently has an average rating of “Hold” and an average target price of $189.08.

Becton, Dickinson and Company Trading Down 0.4%

Shares of BDX stock opened at $154.95 on Friday. The firm has a market capitalization of $44.12 billion, a P/E ratio of 25.28, a P/E/G ratio of 11.07 and a beta of 0.29. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. The stock’s fifty day simple moving average is $163.66 and its 200 day simple moving average is $183.44.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. The business had revenue of $4.49 billion for the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.Becton, Dickinson and Company’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 12.56 EPS for the current fiscal year.

Becton, Dickinson and Company announced that its board has approved a share repurchase plan on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th were given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Tuesday, March 10th. Becton, Dickinson and Company’s payout ratio is 68.52%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.